The once-weekly treatment can be administered at home, offering an alternative to intravenous infusions given every other week in a hospital or clinic.
China is the second country to approve the auto-injector for initiation therapy. Eisai plans to launch the treatment during its 2026 fiscal year, which ends on 31 March 2027.
BREAKING